TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20689328

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium concentration in the dialysate adjusted according to serum calcium, phosphate and PTH
Number of subjects: 72
Study: 19801040

Group type: EXPERIMENTAL
Intervention: PM101 (50 mg/ml, bolus push)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard loading dose of AIV (150 mg, infused at 1.5 mg/ml over 10 minutes)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Rapid loading dose of AIV (150 mg, infused undiluted at 50 mg/ml over 15 seconds)
Number of subjects: 224
Study: 16412749

Group type: EXPERIMENTAL
Intervention: Aspirin and low molecular weight heparin treatment in women with APS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Natural cycle donor insemination (Control)
Number of subjects: 10
Study: 15644572

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 11317114

Group type: EXPERIMENTAL
Intervention: Active therapy
Number of subjects: 148
Study: 9394635

Group type: EXPERIMENTAL
Intervention: Positive frame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative frame
Number of subjects: 0
Study: 8203857

Group type: EXPERIMENTAL
Intervention: Gram-positive prophylaxis with 10(6) U of penicillin i.v. every 6 hours (or 750 mg of vancomycin i.v. q12h if penicillin allergic) in addition to standard antimicrobial prophylaxis.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard antimicrobial prophylaxis (400 mg of norfloxacin orally three times a day, 200 mg of fluconazole orally once a day, and 5 mg of acyclovir per kg of body weight i.v. q12h) without gram-positive prophylaxis.
Number of subjects: 43
Study: 3038722

Group type: EXPERIMENTAL
Intervention: recombinant interferon‐alpha 2A at 10 mU per m2
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: recombinant interferon‐alpha 2A
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 41
Study: 29717197

Group type: EXPERIMENTAL
Intervention: NGM282 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NGM282 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NGM282 (1 mg and 6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NGM282
Number of subjects: 0
Study: 26962902

Group type: EXPERIMENTAL
Intervention: Labor induction between 39 weeks 0 days and 39 weeks 6 days of gestation
Number of subjects: 619

Group type: COMPARATOR
Intervention: Expectant management (waiting for spontaneous onset of labor or medical indication for induction)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Labor induction
Number of subjects: 619

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 619
Study: 24039194

Group type: EXPERIMENTAL
Intervention: 12 hours of intravenous prehydration before HDMTX infusion
Number of subjects: 47

Group type: COMPARATOR
Intervention: 4 hours of intravenous prehydration before HDMTX infusion
Number of subjects: 47
Study: 22743321

Group type: EXPERIMENTAL
Intervention: 12 mg L and 1 mg Z supplementation
Number of subjects: 97
Study: 20591841

Group type: EXPERIMENTAL
Intervention: Remote monitoring of ICD leads
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Systematic interrogation every 3 months
Number of subjects: 40
Study: 19078818

Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (0.5 ml of 2% lidocaine 2 min before arterial puncture)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ethyl chloride (immediately before arterial puncture)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nothing (routine skin preparation before arterial puncture)
Number of subjects: 54
Study: 16008071

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 12442604

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (25 grams carbohydrates)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10517342

Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy or breast conservation treatment
Number of subjects: 227
Study: 7739851

Group type: EXPERIMENTAL
Intervention: 0.2 g caffeine administered orally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caffeine elimination measured at 12 hours post-administration
Number of subjects: 40
Study: 2288833

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nifedipine R 20 mg twice daily
Number of subjects: 100
Study: 340131

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g once daily for 3 consecutive days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole (2 g once daily for 3 consecutive days)
Number of subjects: 60
Study: 30198451

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality plus morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 80
Study: 29021268

Group type: EXPERIMENTAL
Intervention: PLUS (3 sessions/week for 12 weeks, then maintenance classes for 12 additional weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LITE (2 sessions/week for 12 weeks)
Number of subjects: 29
Study: 26116444

Group type: EXPERIMENTAL
Intervention: Interprofessional shared decision-making (IP-SDM) toolkit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes guidelines summary (Control)
Number of subjects: 0
Study: 23628457

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stent (ZES)
Number of subjects: 154
Study: 21802037

Group type: EXPERIMENTAL
Intervention: Contract-Relax group (CR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified Contract-Relax group (MCR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 19884591

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline with epinephrine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nebulized 0.9% saline with epinephrine (Control)
Number of subjects: 46
Study: 16702864

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal rings (360 degrees)
Number of subjects: 72
Study: 14675406

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methotrexate (HDMTX) (6-8 g/m2) with intrathecal methotrexate (ITMTX)
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: XRT and a short course of ITMTX
Number of subjects: 2090

Group type: COMPARATOR
Intervention: ITMTX alone
Number of subjects: 2090

Group type: COMPARATOR
Intervention: HDMTX plus ITMTX
Number of subjects: 2090
Study: 11703217

Group type: EXPERIMENTAL
Intervention: Problem-based health education program (n=18), multidisciplinary approach, cognitive behavioral therapy exercises, 7 sessions over 5 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 38
Study: 9044225

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE) - 20g.d‐1 for 3 d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA) - drink only
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON) - no supplementation
Number of subjects: 9
Study: 7941189

Group type: EXPERIMENTAL
Intervention: Chronic maintenance hemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Renal transplantation
Number of subjects: 20
Study: 3282501

Group type: EXPERIMENTAL
Intervention: 0.25% levobunolol hydrochloride
Number of subjects: 78

Group type: COMPARATOR
Intervention: timolol maleate
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol hydrochloride
Number of subjects: 78

Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 78
Study: 31638433

Group type: EXPERIMENTAL
Intervention: INS + ACA
Number of subjects: 124

Group type: COMPARATOR
Intervention: INS + MET
Number of subjects: 124
Study: 28691866

Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg multiple ascending dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Venetoclax (various doses)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 27486219

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional walking training (CWT)
Number of subjects: 43
Study: 25937511

Group type: EXPERIMENTAL
Intervention: RHS-led gardening intervention (n = 373)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Teacher-led gardening intervention (n = 404)
Number of subjects: 777
Study: 24000874

Group type: EXPERIMENTAL
Intervention: Continuous ACE‐Is users
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Intermittent ACE‐Is users
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Continuous or intermittent users of other antihypertensive drugs
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Never‐users of antihypertensive drugs
Number of subjects: 616

Group type: COMPARATOR
Intervention: ACE‐Is users (continuous or intermittent)
Number of subjects: 616
Study: 20621401

Group type: EXPERIMENTAL
Intervention: Paracetamol 1g intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg intramuscularly
Number of subjects: 30
Study: 18294084

Group type: EXPERIMENTAL
Intervention: MLR MPH (Biphentin), once per day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IR MPH (Ritalin), twice per day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 17081832

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol-enriched snack bar containing 1.5 g phytosterol
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control product containing no phytosterols
Number of subjects: 67
Study: 14998365

Group type: EXPERIMENTAL
Intervention: Clinical estimation by ophthalmologists
Number of subjects: 7
Study: 11293459

Group type: EXPERIMENTAL
Intervention: Thematic relations in concepts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meaningful and salient thematic relations
Number of subjects: 0
Study: 9146849

Group type: EXPERIMENTAL
Intervention: Glibenclamide (Gb)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4-trans-hydroxy-glibenclamide (M1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3-cis-hydroxy-glibenclamide (M2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7712966

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 141
Study: 3282531

Group type: EXPERIMENTAL
Intervention: 5 mg oral pimobendane (UD-CG 115)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg oral pimobendane (UD-CG 115)
Number of subjects: 8
Study: 30336168

Group type: EXPERIMENTAL
Intervention: Film-forming chlorhexidine gluconate (CHG) preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water-soluble chlorhexidine gluconate (CHG) preparation
Number of subjects: 0
Study: 28349496

Group type: EXPERIMENTAL
Intervention: 6-gingerol 10 mg orally twice daily for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 25996351

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study: 23406156

Group type: EXPERIMENTAL
Intervention: Rhinoplasty for non-deviated nose
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Rhinoplasty for deviated nose
Number of subjects: 191

Group type: COMPARATOR
Intervention: Comparison of non-deviated vs deviated nose groups
Number of subjects: 191
Study: 19942303

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT) + Endurance Training (ET)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Endurance Training (ET) only
Number of subjects: 21
Study: 19629514

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (10 treatments within 17 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 43
Study: 17346595

Group type: EXPERIMENTAL
Intervention: In-vitro bond strength testing with mini-twin metallic premolar brackets bonded to 60 extracted premolars at 10 minutes, 24 hours, 1 week, and 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: In-vivo bond strength testing with mini-twin metallic premolar brackets bonded to 60 premolars in 22 volunteers at 10 minutes, 24 hours, 1 week, and 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Survival analysis for bond failure probability in both in-vitro and in-vivo environments.
Number of subjects: 60
Study: 15519257

Group type: EXPERIMENTAL
Intervention: DDD‐CLS mode pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: DDI mode pacing (control group)
Number of subjects: 50
Study: 12529072

Group type: EXPERIMENTAL
Intervention: AOD disorders
Number of subjects: 797

Group type: COMPARATOR
Intervention: No AOD disorders
Number of subjects: 797
Study: 9738637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 391

Group type: COMPARATOR
Intervention: CRP levels
Number of subjects: 391

Group type: COMPARATOR
Intervention: SAA levels
Number of subjects: 391
Study: 8054959

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (200 micrograms Cr as picolinate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 38
Study: 2856543

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (400 mcg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 11
Study: 30312985

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5000 IU/w for insufficiency, 10,000 IU/w for mild deficiency, 15,000 IU/w for severe deficiency) plus lifestyle guidance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received health education and lifestyle guidance
Number of subjects: 100
Study: 26638037

Group type: EXPERIMENTAL
Intervention: Scripted PNES diagnosis and inpatient psychiatry consult (n=10)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Weekly follow‐up phone calls in addition to scripted diagnosis and inpatient psychiatry consultation (n=15)
Number of subjects: 37

Group type: COMPARATOR
Intervention: PNES diagnosis delivered per the discretion of the attending physician with advice to seek mental health assistance in the community (n=12)
Number of subjects: 37
Study: 25546486

Group type: EXPERIMENTAL
Intervention: High-rate cut-off ICD programming (arm B)
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Delayed VT therapy ICD programming (arm C)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Conventional ICD programming (arm A)
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: First inappropriate ICD therapy
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: First appropriate ICD therapy
Number of subjects: 1498
Study: 23546631

Group type: EXPERIMENTAL
Intervention: Pre-operative electroacupuncture (PrEA)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Post-operative electroacupuncture (PoEA)
Number of subjects: 178
Study: 20494656

Group type: EXPERIMENTAL
Intervention: Symptom-to-balloon time <3 hours
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Symptom-to-balloon time 3 to 5 hours
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Symptom-to-balloon time >=5 hours
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Symptom-to-balloon time >=5 hours (adjusted)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Symptom-to-balloon time
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Left ventricular systolic ejection fraction <=40%
Number of subjects: 686
Study: 18602312

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) used in combination with autologous bone grafting
Number of subjects: 34

Group type: COMPARATOR
Intervention: Autologous bone grafting alone
Number of subjects: 34
Study: 17023234

Group type: EXPERIMENTAL
Intervention: Once-Daily Controlled-Release Carvedilol CR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-Daily Immediate-Release Carvedilol IR
Number of subjects: 0
Study: 12794835

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etanercept (after switching from placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etanercept cessation
Number of subjects: 30
Study: 11027115

Group type: EXPERIMENTAL
Intervention: Leflunomide (Arava‐Aventis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate or Sulfasalazine
Number of subjects: 0
Study: 8803463

Group type: EXPERIMENTAL
Intervention: Uro-Vaxom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and Uro-Vaxom
Number of subjects: 0
Study: 1622643

Group type: EXPERIMENTAL
Intervention: Radiotherapy + tamoxifen 30 mg daily for 48 weeks
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 3640

Group type: EXPERIMENTAL
Intervention: Irradiated patients
Number of subjects: 3640

Group type: COMPARATOR
Intervention: Non-irradiated patients
Number of subjects: 3640
Study: 6381314

Group type: EXPERIMENTAL
Intervention: Cephalexin b.i.d.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cephalexin q.i.d.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both treatments (b.i.d. and q.i.d.)
Number of subjects: 65
Study: 29934701

Group type: EXPERIMENTAL
Intervention: Flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (diosmin in combination with hesperidin, diosmetin, isoroifolin, and linarin in purified micronized fraction)
Number of subjects: 154
Study: 26910697

Group type: EXPERIMENTAL
Intervention: Postoperative arnica cream treatment (Group 1, n = 36)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Postoperative mucopolysaccharide polysulfate cream treatment (Group 2, n = 36)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (Group 3, n = 36)
Number of subjects: 108
Study: 24281981

Group type: EXPERIMENTAL
Intervention: Carbetocin (initial dose 10 μg, increments/decrements of 5 μg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 40
Study: 22469168

Group type: EXPERIMENTAL
Intervention: Telephone-coaching program
Number of subjects: 950

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 950
Study: 20357486

Group type: EXPERIMENTAL
Intervention: Dpg-Pol extracts (100 HEPL/ml) administered with 6 up-dosing and monthly maintenance injections for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18478481

Group type: EXPERIMENTAL
Intervention: Low dose (LD, 1.5 g NS day (‐1))
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: High dose (HD, 3.0 g NS day (‐1))
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 656
Study: 15838189

Group type: EXPERIMENTAL
Intervention: SUMIT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 0
Study: 12496528

Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transthoracic esophagectomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both surgical approaches
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preoperative immune function
Number of subjects: 20

Group type: COMPARATOR
Intervention: Duration of anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preoperative interferon-gamma production
Number of subjects: 20
Study: 10910855

Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus clonidine (LC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clonidine (C)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Levobupivacaine (L)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clonidine groups (C and LC)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study: 8660169

Group type: EXPERIMENTAL
Intervention: Antiviral treatment (specific agents not detailed)
Number of subjects: 76
Study: 1381018

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nifedipine (40 mg daily)
Number of subjects: 53
Study: 6347498

Group type: EXPERIMENTAL
Intervention: Coffee after placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Coffee after propranolol (nonselective beta-blockade)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Coffee after metoprolol (beta 1-selective blockade)
Number of subjects: 12
Study: 29428830

Group type: EXPERIMENTAL
Intervention: Supervised exercise and home-based exercise (combined)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 213
Study: 27419856

Group type: EXPERIMENTAL
Intervention: Group medical visits (GMVs) incorporating CAM therapies (mindfulness techniques, movement, guided imagery, relaxation training, yoga, qigong, t'ai chi)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 42
Study: 24144212

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day hydroxyurea (HU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 20 mg/kg/day hydroxyurea (HU)
Number of subjects: 61
Study: 22108765

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: FM education
Number of subjects: 114
Study: 19888959

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery within an ERP
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open surgery within an ERP
Number of subjects: 22